Exparel sales up 22.4% after CMS offers coverage — 3 quick insights

For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.

Three quick insights:

1. Net sales of Exparel reached $90.6 million in the first quarter of 2019, a year-over-year increase of 22.4 percent.

2. ASCs and oral surgery centers were the key drivers of Exparel utilization.

3. Pacira's total first-quarter revenues were $91.3 million, up from $74.6 million in the first quarter of 2018.

More articles on anesthesia:
SouthEast Eye Specialists adds Drs. JD Bonner, Will Whitmire — 3 insights
Happy 25th birthday Arizona Institute of Medicine and Surgery — 4 insights
Meet Chesapeake Urology's newest specialist — 3 highlights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months